Milestone Pharmaceuticals Inc · Q4 2021 earnings

Briefing

Milestone Pharmaceuticals' financial position and operations were presented fairly, with a recognized revenue of $15 million from a license agreement.

Milestone Pharmaceuticals reported a revenue of $15 million due to a license agreement with Ji Xing. The company's operations are focused on developing and commercializing cardiovascular medicines, with its lead product candidate, etripamil, in clinical development. The company had cash and cash equivalents of $114.1 million as of December 31, 2021, and believes this is sufficient to fund planned operations for at least one year.

• Revenue of $15 million was recognized from a license agreement with Ji Xing for etripamil development and commercialization rights in specific territories.
• The company's lead product candidate, etripamil, is being developed as a rapid-onset nasal spray for cardiovascular indications.
• Cash and cash equivalents totaled $114.1 million as of December 31, 2021, expected to fund operations for at least a year.
• Operating losses and negative cash flows are expected to continue for the foreseeable future.

Headline financials

Revenue & EPS history

Milestone Pharmaceuticals anticipates continuing to incur losses for at least the next several years. The Company currently plans to raise additional funding as required based on the status of its clinical trials and projected cash flows.